ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), today announced that its subsidiary, Talem Therapeutics LLC (“Talem”), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated. The agreement builds upon Talem’s extensive antibody development expertise and its access to LENSai™ in silico software technology to further the development and commercialization of OmniChicken-derived antibody panels against B7H3, CD38 and TIM3, which are immuno-oncology targets. The collaboration leverages antibodies from the OmniChicken discovery technology, the industry’s first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires for the discovery of therapeutic antibodies, with Talem’s advanced antibody development technologies aimed at optimizing clinical success.
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results of a new study conducted by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), that has shown the continued resilience of PolyTope® TATX-03 in broadly neutralizing SARS-Co-V-2 variants, including two Omicron sublineages that had not been previously tested.